Carbapenem-resistant Gram-negative bacteria (CR-GNB) represent an increasing hazard in healthcare settings. A central question concerning the treatment of invasive infections caused by CR-GNB involves the use of combination therapy. Potential advantages of combination therapy include improved efficacy due to synergy, while the disadvantages include adverse events and increased antibiotic use with a potential drive towards resistance. Several observational studies have examined whether combination therapy offers an advantage over colistin/ polymyxin monotherapy. We highlight the inherent limitations of these studies related to their observational design and sample size to show why they do not at present provide an answer to the question of combination versus monotherapy. This distinction is important to guide clinical practice until solid evidence has been obtained and to enable the recruitment of patients into randomized controlled trials. A few randomized controlled trials examining specific combinations have recently been completed or are ongoing. Currently, however, there is no evidence-based support for most combination therapies against CR-GNB, including colistin/carbapenem combination therapy.
Introduction
Carbapenem-resistant (CR) Gram-negative bacteria (GNB) are gaining increasing importance in healthcare settings, especially in high-dependency units and among critically ill patients. 1 These bacteria are frequently resistant to all antibiotics except colistin, some aminoglycosides and variably tigecycline, posing a serious challenge for treatment. Several observational clinical studies have claimed an advantage for colistin-based combination therapy and, in consequence, combination therapy has become the standard of care for many physicians for infections caused by CR-GNB. 2 -5 In this article we outline the limitations of existing empirical data on combination therapy and the implications of current knowledge for clinical practice and research.
Colistin is a last-resort antibiotic for bacteria resistant to other antibiotics. It was introduced over 50 years ago without its efficacy having been assessed in randomized controlled trials (RCTs). Historical data from the 1960s suggest that it is less efficacious and more toxic than aminoglycosides and indeed when these became available they rapidly replaced colistin. Contemporary observational data suggest that colistin is less effective than b-lactams when these are active in vitro. 6, 7 Combination therapy, commonly consisting of colistin combined with an antibiotic to which the isolate is resistant (e.g. a carbapenem), has been proposed to improve the outcomes of colistin monotherapy. The question is pertinent specifically for CR-GNB, as there is no need for colistin against carbapenem-susceptible (CS) bacteria. While in vitro studies can identify synergistic antibiotic combinations, 8 there are no clinical studies showing that synergy correlates with improved outcomes. 9 Thus, clinical studies are needed to guide clinical practice.
Sources of bias in the existing studies
Many of the studies to date have included both CS and CR isolates. 10 -14 An observational retrospective design implies that the researchers had no control over the patients' treatment and the indications for treatment. A patient is more likely to receive colistin monotherapy if infected by a pathogen resistant to all other antibiotics. Conversely, patients receiving combination therapy might be infected by bacteria susceptible to carbapenems or have polymicrobial infections with resistant and susceptible strains. Patients with CR-GNB are likely to be more severely ill at baseline than patients with CS bacteria. Thus, the comparison between monotherapy and combination therapy potentially carries a selection bias. Furthermore, those patients in the combination therapy group infected with CS bacteria are treated with effective antibiotics, e.g. carbapenems for CS-GNB, again biasing the comparison in favour of combination therapy. Daikos et al. 14 recently demonstrated this nicely. In their study, 53% of patients with bacteraemia caused by carbapenemase-producing Klebsiella pneumoniae had strains that were phenotypically non-resistant to carbapenems. Mortality was higher among patients with CR (MIC .8 mg/L) K. pneumoniae bacteraemia than patients with nonresistant isolates (when all received combination therapy), and an advantage for carbapenems combined with in vitro inactive agent(s) was observed in the subgroup of patients with CS, but not in the subgroup of patients with CR, K. pneumoniae bacteraemia. Thus, while combination therapy was associated with lower overall mortality, the difference probably reflected the better outcomes seen in the subgroup of patients with CS-GNB. Tumbarello et al. 12 concluded that combination therapy including a carbapenem is the most effective treatment option for carbapenemase-producing K. pneumoniae bacteraemia. In 5/36 patients treated with meropenem-combination therapy the isolate was fully susceptible to meropenem and all the patients survived. Similarly, in the study by Batirel et al., 15 a colistin/sulbactam combination therapy was associated with better outcomes than colistin monotherapy, but Acinetobacter baumannii is frequently susceptible to sulbactam.
A small study size does not permit adjustment for mortality risk factors other than treatment. Clearly, among patients with CR-GNB infections comorbidities and underlying conditions are major contributors to the final patient outcome. At least 7-10 variables are known to affect mortality in severe infections. 16 Thus, the number of patients needed in a cohort study to examine the independent association of treatment with mortality is several hundreds to thousands, considering a recommended events-per-independent variable ratio of 10:1. 17 The conclusion of Qureshi et al. 13 in favour of combination therapy for the definitive therapy of bacteraemia due to KPC-producing K. pneumoniae is based on 34 patients receiving definitive treatment and 13 deaths, while the conclusion of Tumbarello et al.
12 that combined treatment with two or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be more effective than monotherapy, is based on 16 patients receiving the carbapenem combination regimen that was associated with lower mortality (meropenem/tigecycline/colistin). Furthermore, pointing to a specific treatment regimen 10 -12,18,19 carries the risk of a chance finding of benefit because of the many different treatment regimens in a non-interventional study. The ratio between the number of regimens and the number of patients in studies reporting the number of different treatment regimens ranged between 1: 10 to 10: 10 (median 4: 10). 12 -15,20 -24 The risk for spuriously significant associations between individual treatment regimens and mortality is therefore high.
Among the important covariates for adjustment is the appropriateness of the initial empirical antibiotic treatment. 25 Inappropriate empirical antibiotic treatment is a likely confounder in the comparison between monotherapy and combination therapy, since patients receiving combination therapy are a priori more likely to have received covering empirical treatment (i.e. bacteria are susceptible to one or both agents) by simple probability. Only two studies have reported the comparative time to covering antibiotic treatment and, indeed, the duration was longer among patients treated with colistin monotherapy. 15, 18 Most studies did not adjust for the appropriateness of empirical antibiotic treatment when comparing between colistin monotherapy and combination therapy.
Assessing combination therapy, as such, lacks biological rationale. Certain antibiotic combinations have been shown to be synergistic in vitro. 8 These specific combinations should be examined in clinical studies; other combinations might be antagonistic. Several studies have reported on the effects of 'combination therapy', consisting of a mix of treatment regimens of different classes and different combinations. 12 -15,26 Using 'combination therapy' as the factor analysed invites selection bias, as mentioned above. Furthermore, the definitions of combination therapy differ in the different studies (any two drugs, at least one covering, both covering, etc.) so that a single generalizable conclusion cannot be made and the implications for clinical practice are unclear.
The dosing of colistin has undergone a major revision in recent years. Pharmacokinetic analyses have shown that a loading dose is necessary to rapidly reach levels above the MIC. 27 Without a loading dose, it might take 3 days for colistin to reach a therapeutic level. The total standard daily dose currently recommended is 9 million international units (MIU; 1 MIU is equivalent to 30 mg colistin base activity). 28 Loading doses were not reported in most of the studies examining colistin combination therapy, and the total daily dose of colistin monotherapy was lower than recommended in most studies, biasing the results against colistin monotherapy.
Summary of existing studies
Finally, as for all interventions, clinical practice must be guided by the totality of the available data. We searched for studies that compared colistin monotherapy versus colistin-based combination therapy for the treatment of carbapenemase-producing GNB or CR-GNB, and reported quantitatively on the association between the treatment regimen and all-cause mortality, preferably at a fixed point in time (14 -30 days), regardless of study design. We found 12 retrospective cohort studies or case series, 4,10 -13,15,18 -21,24,26 two prospective observational studies 22, 23 and two RCTs. 29, 30 We plotted the results of all-cause mortality for colistin monotherapy versus combination therapy in a forest plot, subgrouped by the type of combination regimen (unadjusted results in the observational studies). Inspection of the forest plot shows an advantage for combination therapy only in the subgroup of studies evaluating 'any combination' (mixed comparators; Figure 1 ). None of the individual studies or their pooled result shows a difference in mortality between colistin alone and colistin/carbapenem combination therapy. Pooling the only two RCTs shows similar mortality for colistin monotherapy versus colistin/rifampicin combination therapy.
Conclusions
Mortality with colistin monotherapy is unacceptably high, but this does not mean that combination therapy performs better. The implication of accepting combination therapy for CR-GNB is the excessive use of antibiotics in hospitals where these bacteria are prevalent, resulting in a vicious cycle of antibiotic use and JAC induction/maintenance of resistance. Adding non-covering antibiotics, especially carbapenems, is not without potential harm to the individual treated. The added antibiotics might favour the persistence of CR-GNB colonization, 31 the acquisition of other CR-GNBs, 32 the development of Clostridium difficile or fungi and other adverse events. Observational studies are important. However, these have to adhere to robust methodological standards. Ultimately, we need RCTs to test specific combination therapies versus colistin alone, aminoglycosides alone or other relevant monotherapies for CR bacteria, with treatments and dosing regimens that are standardized. Lacking RCTs for most combinations, we urge clinicians to judiciously examine the available data before adopting combination therapy as the standard of care. The two largest research financing agencies (the NIH and the European Commission) are supporting RCTs comparing colistin/carbapenem combination therapy versus colistin monotherapy for invasive infections caused by CR-GNB (NCT01732250, NCT01597973). We hope that evidence will emerge in the near future to better guide clinical practice.
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